A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Latest Information Update: 03 Jan 2024
At a glance
- Drugs Avapritinib (Primary)
- Indications Colon cancer; Colorectal cancer; Duodenal cancer; Gastric cancer; Gastrointestinal stromal tumours; Peritoneal cancer; Rectal cancer; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept; Registrational; Therapeutic Use
- Acronyms NAVIGATOR
- Sponsors Blueprint Medicines
- 27 Dec 2023 Results from a post hoc data analysis of the global Phase 1 NAVIGATOR and Phase 1/2 China bridging (CS3007-101) studies presented in the CStone Pharmaceuticals Media Release
- 27 Dec 2023 Results of post hoc analysis from the global Phase 1 NAVIGATOR study and the Chinese bridging Phase 1/2 CS3007-101 study in patients with advanced gastrointestinal stromal tumors (GIST), presented in the CStone Pharmaceuticals Media Release.
- 30 Nov 2023 Results (n=160) of post-hoc analysis of two studies (NAVIGATOR and CS3007-001 trials) assessing the clinical benefit of avapritinib in patients with non-PDGFRA-mutant, KIT-only-mutant gastrointestinal stromal tumors (GISTs), published in the Clinical Cancer Research.